Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview.

Columnist Teri Sforza writes that studies have found that semaglutide reduced alcohol intake, binge drinking and relapse ...

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview.

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to ...

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Serena Williams is serving up an honest look into her weight loss. The tennis star—who shares daughters Alexis, 6, and Adira, ...

An observational study published in JAMA Oncology looks at GLP-1 receptor agonists and cancer risk in adults with obesity. Prof Paul Pharoah, Professor of Cancer Epidemiology, Cedars-Sinai Medical ...